Emcure Pharmaceuticals Limited (NSE:EMCURE)
India
· Delayed Price · Currency is INR 1,455.50
+1.00 (0.07%)
At close: Feb 27, 2026
Emcure Pharmaceuticals Revenue
Emcure Pharmaceuticals had revenue of 23.63B INR in the quarter ending December 31, 2025, with 20.42% growth. This brings the company's revenue in the last twelve months to 88.50B, up 17.20% year-over-year. In the fiscal year ending March 31, 2025, Emcure Pharmaceuticals had annual revenue of 78.96B with 18.59% growth.
Revenue (ttm)
88.50B
Revenue Growth
+17.20%
P/S Ratio
3.12
Revenue / Employee
13.15M
Employees
6,731
Market Cap
275.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 78.96B | 12.38B | 18.59% |
| Mar 31, 2024 | 66.58B | 6.72B | 11.23% |
| Mar 31, 2023 | 59.86B | 1.30B | 2.23% |
| Mar 31, 2022 | 58.55B | 8.22B | 16.33% |
| Mar 31, 2021 | 50.33B | -150.80M | -0.30% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2012 | Pro | Pro | Pro |
| Mar 31, 2011 | Pro | Pro | Pro |
| Mar 31, 2010 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Gland Pharma | 61.13B |
| Wockhardt | 31.74B |
| Piramal Pharma | 88.71B |
| Ajanta Pharma | 52.02B |
| Ipca Laboratories | 95.06B |
| Eris Lifesciences | 30.65B |
| NATCO Pharma | 45.63B |
| Alembic Pharmaceuticals | 72.67B |